- Celonic Group has signed a multi-year commercial manufacturing agreement with LINDIS Biotech for the production of catumaxomab.
- Manufacturing will take place at Celonic’s Heidelberg, Germany facility, supporting the commercial supply of the bispecific monoclonal antibody.
Celonic Group has entered a multi-year commercial manufacturing agreement with LINDIS Biotech to produce catumaxomab, a bispecific monoclonal antibody designed for the treatment of malignant ascites in patients with EpCAM-positive carcinomas. The agreement strengthens Celonic’s role as a CDMO in biologics contract manufacturing.
Catumaxomab is a first-in-class therapy for malignant ascites, a condition marked by fluid accumulation in the peritoneal cavity due to advanced-stage cancer. The treatment is intended for patients who are ineligible for other systemic anticancer therapies.
Under the terms of the agreement, Celonic will leverage its GMP manufacturing expertise at its state-of-the-art facility in Heidelberg, Germany. This collaboration aims to ensure a reliable commercial supply of catumaxomab.
Dr. Horst Lindhofer, CEO of LINDIS Biotech, emphasized the importance of the partnership, stating: “Partnering with Celonic Group is a vital part of our mission to bring catumaxomab to patients suffering from malignant ascites and fill this unmet clinical need. With Celonic’s proven manufacturing capabilities and commitment to quality, we are confident in their ability to ensure a reliable and high-quality supply of our innovative therapy.”
Samanta Cimitan, PhD, CEO of Celonic Group, highlighted the company’s commitment to biologics manufacturing, noting that the agreement underscores Celonic’s role in contract manufacturing for innovative biologics addressing unmet medical needs.
Stay ahead of trends and best practices
